文献速递浆细胞疾病

铜-64标记达雷妥尤单抗在多发性骨髓瘤患者中识别CD38+细胞的首次人体成像

Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab.
PubMed 文献 · Blood Adv · 2020-01-01

该1期试验纳入12例未接受达雷妥尤单抗治疗的多发性骨髓瘤患者,评估64Cu-daratumumab PET/CT的安全性和可行性。结果显示该成像方法安全且可全身成像,45 mg未标记达雷妥尤单抗预处理时图像质量最佳,计划与FDG PET/CT进行敏感性和特异性比较。

要点

  • 64Cu-daratumumab PET/CT在多发性骨髓瘤患者中安全可行
  • 45 mg未标记达雷妥尤单抗预处理可优化图像质量
  • 该方法的敏感性和特异性尚需与FDG PET/CT对比验证

核心结论

  • 64Cu-daratumumab PET/CT可安全地进行多发性骨髓瘤全身成像。
  • 45 mg未标记达雷妥尤单抗是去除背景信号而不饱和靶点的最佳剂量水平。

研究设计与样本

  • 1期临床试验,纳入12例未接受达雷妥尤单抗治疗的多发性骨髓瘤患者。
  • 患者注射15 mCi/5 mg的64Cu-daratumumab前接受0、10、45或95 mg未标记达雷妥尤单抗预处理。

主要发现

  • 未标记达雷妥尤单抗和64Cu-daratumumab均未观察到显著不良事件。
  • 在测试的剂量水平中,45 mg未标记达雷妥尤单抗在去除背景信号方面最优。

关键数值与推荐

  • 注射剂量为15 mCi/5 mg的64Cu-daratumumab。
  • 未标记达雷妥尤单抗预处理剂量为0 mg(n=3)、10 mg(n=3)、45 mg(n=3)或95 mg(n=3)。

临床怎么用

  • 64Cu-daratumumab PET/CT可作为多发性骨髓瘤CD38靶向成像的安全可行方法。
  • 采用45 mg未标记达雷妥尤单抗预处理有助于优化图像质量。

局限性

  • 本研究为1期试验,样本量小(12例)。
  • 尚未与FDG PET/CT进行敏感性和特异性的头对头比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is one of the most widely used imaging techniques to detect multiple myeloma (MM). Intracellular FDG uptake depicts in vivo metabolic activity, which can be seen in both malignant and nonmalignant cells, resulting in limited sensitivity and specificity. Our group showed preclinically that tracing MM dissemination using a CD38-directed human antibody, daratumumab, that is radioconjugated with 64Cu via the chelator DOTA (64Cu-daratumumab), led to improved sensitivity and specificity over that of FDG. Here, we report the results of a phase 1 trial designed to (1) assess the safety and feasibility of 64Cu-daratumumab PET/CT and (2) preliminarily evaluate and characterize the ability of 64Cu-daratumumab to accurately detect or exclude MM lesions. A total of 12 daratumumab-naive patients were imaged. Prior to the injection of 15 mCi/5 mg of 64Cu-daratumumab, patients were treated with 0 (n = 3), 10 (n = 3), 45 (n = 3), or 95 mg (n = 3) of unlabeled daratumumab to assess its effect on image quality. No significant adverse events were observed from either unlabeled daratumumab or 64Cu-daratumumab. Of the dose levels tested, 45 mg unlabeled daratumumab was the most optimal in terms of removing background signal without saturating target sites. 64Cu-daratumumab PET/CT provided safe whole-body imaging of MM. A trial comparing the sensitivity and specificity of 64Cu-daratumumab PET/CT with that of FDG PET/CT is planned. This trial was registered at www.clinicaltrials.gov as #NCT03311828.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Krishnan A, Adhikarla V, Poku EK, et al. Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab. Blood Adv. 2020. PMID: 33095874. doi:10.1182/bloodadvances.2020002603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。